CT-155: Prescription digital therapeutic
Phase 3
Therapeutic Area: Central Nervous System
Indication: Schizophrenia
Anchored in external partnership or acquisition
US FDA Breakthrough Therapy Designation
People experiencing negative symptoms of schizophrenia, such as emotional withdrawal and lack of pleasure, often have limited access to psychotherapy, and can be socially isolated or disconnected from everyday life. It can also impact productivity which has a societal and economic impact.
Boehringer Ingelheim is investigating an evidence-based prescription digital therapeutic (PDT) that provides psychosocial intervention techniques to people experiencing negative symptoms of schizophrenia.
Installed on a smartphone, the PDT is supposed to be prescribed by healthcare professionals as an adjunctive to standard of care therapy to treat the behavioral dimensions of diseases and conditions. This intervention may help people living with negative symptoms of schizophrenia take daily actions to adjust thought patterns and behavior. This could result in tangible progress and lasting changes in their lives.
This supports Boehringer Ingelheim’s approach to provide more holistic support for people living with chronic and complex mental health conditions through digital therapeutics.